Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443053 | 0.91 | L3MBTL1 (0.49) | MAPTELANEPLA2G10CCR1L3MBTL1 | |
| SCHEMBL5448202 | 0.87 | L3MBTL1 (0.56) | MAPTELANEL3MBTL1LMNATSHR | |
| SCHEMBL4688131 | 0.86 | MAPT (0.53) | MAPTELANERAB9ANPC1POLB | |
| SCHEMBL5758430 | 0.85 | ELANE (0.65) | MAPTELANERAB9ANPC1POLB | |
| SCHEMBL5755679 | 0.84 | MAPT (0.56) | MAPTELANERAB9ANPC1POLB | |
| SCHEMBL5435796 | 0.84 | CCR1 (0.54) | ELANEPLA2G10CCR1LMNAHPGD | |
| SCHEMBL5434807 | 0.83 | ELANE (0.51) | ELANEPLA2G10CCR1LMNAHPGD | |
| SCHEMBL4022981 | 0.83 | MAPT (0.53) | MAPTELANERAB9ANPC1POLB | |
| SCHEMBL5434666 | 0.82 | ELANE (0.55) | MAPTELANEPLA2G10RAB9ANPC1 | |
| SCHEMBL5441836 | 0.82 | ELANE (0.54) | ELANEPLA2G10CCR1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | MAPT 1850/4885ELANE 2/4885PLA2G10 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.